The 72-year-old patient was unable to mount her own immune defense against the SARS-CoV-2 virus because of chronic lymphocytic leukemia, which compromises normal immunity and immunoglobulin...
Agency veteran Dr Janet Woodcock is the new interim FDA commissioner appointed by president Joe Biden to replace The post Biden appoints veteran Woodcock as interim...
Thermo Fisher Scientific is acquiring Mesa Biotech for about $450 million in cash, and will pay an additional $100 million in cash if certain milestones are...
Researchers are working on a type of vaccine technology using nanoparticles that is less expensive and does not need to be stored at very low temperatures...
With multiple COVID-19 vaccines being distributed across the world, companies focused on other medical conditions are grabbing the Street's attention. One such disorder is diabetes, which...
Mammoth and IDbyDNA are among subcontractors under a four-year, up-to-$36.7 million CRISPR diagnostics contract inked by DoD’s Defense Advanced Research Projects Agency (DARPA) with prime contractor...
A promise by president-elect Joe Biden to carry out 100 million coronavirus vaccinations in his first 100 days The post Fauci backs Biden’s plan for 100...
Johnson & Johnson published interim Phase I/IIa data in the New England Journal of Medicine showing the company's single-dose Covid-19 vaccine candidate created an immune response
South Korea’s Celltrion has announced encouraging top-line results for its potential antibody therapy for COVID-19, with the first The post Celltrion closes in on COVID-19 antibody...
Analysts highlight Sorrento’s "burgeoning portfolio of assets spanning three distinct therapeutic areas (non-opioid pain management, oncology and COVID-19).”
C5 inhibition isn’t the answer to the search for treatments for severe Covid-19 after all. Alexion is pausing enrollment to a Phase III study testing Ultomiris,...
Massive vaccine distribution efforts take a lot of coordination. The rollout of the Salk polio vaccine in the US in 1955 holds lessons for those delivering...
C5 inhibition isn’t the answer to the search for treatments for severe Covid-19 after all. Alexion is pausing enrollment to a Phase III study testing Ultomiris,...
J& J is on track to roll out a single-shot coronavirus vaccine in March, and plans to have clear data on how effective it is by...
Regeneron Pharmaceuticals has signed an agreement with the U.S. for the additional supply of 1.25 million doses of its antibody cocktail for the use in non-hospitalized...
Two in five Americans say they don't want a COVID-19 vaccine, which is a problem. Finding out what Americans do want from a vaccine might help.
CNBC Exclusive: CNBC Transcript: Pfizer Chairman and CEO Albert Bourla speaks with CNBC’s “Squawk Box” today about the Covid vaccine manufacturing outlook. Q3 2020 hedge fund...
Antiviral protein MDA-5 senses viral replication and governs immune response to SARS-CoV-2 Credit: Sanford Burnham Prebys Medical Discovery Institute LA JOLLA, CALIF. – Jan 12, 2020...
Coronavirus-focused stocks have been prone to surge majestically after the announcement of positive news. Last Friday, Applied DNA Sciences (APDN) played by the rulebook. Shares more...
With vaccine shortages looming, experts are debating whether it is important to receive two doses or whether it's better to give one dose to more people...
COVID-19 has compressed bioprocessing timelines, leaving no room for uncertainty in the characterization of raw materials and contaminants. The post Bioprocessing in a Post-COVID-19 World appeared...
Scientists and government sources claimed today that Johnson & Johnson’s single-jab COVID-19 vaccine could be given emergency use authorization as early as next month, according to...
Moderna announced that Israel’s Ministry of Health has granted authorization for the use of its COVID-19 vaccine (mRNA-1273). Shares advanced 1.7% in Tuesday’s pre-market trading. Israel’s...
BioSpace reviewed the top 10 novel drug approvals of 2020, loosely based on projected earnings in the upcoming years.
The COVID-19 vaccine developed by AstraZeneca and Oxford University has been approved by the Indian drug regulator for emergency use,
An unprecedented pandemic did not stop the US stock market from finishing 2020 on a high note. The S&P 500 ended a highly volatile year at...
Data from Phase 3 clinical trial confirm the investigational vaccine known as mRNA-1273 was 94.1% efficacious in preventing symptomatic coronavirus disease
The Covid-19 vaccine developed by British drugmaker AstraZeneca Plc and Oxford University will likely be authorized for emergency use in the United States in April 2021,...
Sinopharm announced that the Chinese biopharmaceutical company's Covid-19 vaccine candidate had an efficacy rate of 79% based on interim analysis of Phase III trials.
Pfizer (PFE) & German partner BioNTech (BNTX) have won another order from the European Union to supply an additional 100 million doses of its COVID-19 vaccine...